Atlas Trials

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Clinical trial NCT03700905 · UNKNOWN

Trial details

NCT number
NCT03700905
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Head and Neck Cancer
Start date
2018-08-21
Primary completion
2024-05-01
Enrollment
276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.